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Abstract
Cytogenetic lesions do not completely explain clinical heterogeneity of chronic lymphocytic leukemia (CLL). 
The 2016 revision of the World Health Organization classification 2008 indicated that molecular lesions of TP53, 
NOTCH1, SF3B1 and BIRC3 have potential clinical relevance and could be integrated into an updated risk profile. 
The negative clinical implications of TP53 disruptions are well constituted and patients with these mutations 
should be considered for novel, small molecule signal transduction inhibitors therapies. Mutations of NOTCH1, 
SF3B1 and BIRC3 are associated with poor prognosis. Patients with mutated SF3B1 or NOTCH1 genes present 
shorter time to first treatment compared to unmutated group. NOTCH1 mutations are related to a high risk of 
Richter’s syndrome transformation, especially in case of TP53 disruptions’ coexistence. Large studies on MYD88 
mutations in CLL have not explained clearly their clinical importance. 
The aim of this paper is to provide a comprehensive review on novel molecular aberrations identified in CLL. 
(Folia Histochemica et Cytobiologica 2017, Vol. 55, No. 3, 95–106)
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Introduction
Chronic lymphocytic leukemia (CLL) is one of the 
most common types of leukemia in adults and is 
characterized by the accumulation of malignant B 
CD5+ lymphocytes in the peripheral blood (PB) and 
lymphoid organs [1]. CLL is a highly heterogeneous 
disease presenting either stable course with above 
15 years survival or rapidly progressive one leading 
to death within a year of diagnosis or to transforma-
tion to an aggressive lymphoma, known as Richter’s 
syndrome (RS) [2–5]. Clinical heterogeneity of CLL 
explains the need for identification of prognostic and 
predictive factors.
In recent years, our knowledge of the genetics of 
CLL has significantly increased and provided many 
clinical biomarkers. The currently used ones include 
immunophenotype markers such as CD38 and ZAP-
70 expression on B lymphocytes surface and mo-
lecular lesions of well-established prognostic value: 
mutational status of IGHV (immunoglobulin heavy 
chain variable region) gene or TP53 mutations [6]. 
Furthermore, in the year 2000 Döhner et al. [7] ap-
plied FISH (interphase fluorescence in situ hybridi-
zation) cytogenetic analysis to evaluate cytogenetic 
lesions in CLL, finding chromosomal abnormalities in 
over 80% of patients. By correlating FISH lesions with 
the course of the disease, a hierarchical model based 
on five risk categories was designed. Patients with the 
17p13 deletion were assigned the worst prognosis, 
followed by cases carrying the 11q22-q23 deletion, 
trisomy 12, normal karyotype and 13q14 deletion [7].
Recent studies based on NGS (next generation 
sequencing) technology have revealed previously un-
known genomic alterations in CLL, such as mutations 
of NOTCH1 (neurogenic locus notch homolog pro-
tein 1), SF3B1 (splicing factor 3B subunit 1), BIRC3 
(baculoviral IAP repeat-containing protein 3) and 
MYD88 (myeloid differentiation primary response 
gene 88), which provide additional information of 
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CLL prognosis [8–11]. Rossi et al. [12] regarded that 
integration of these new mutational disruptions with 
cytogenetic model results in more precise prediction 
of survival compared to the Döhner model alone. 
The 2016 revision of the World Health Organization 
classification reported that novel molecular lesions 
have a potential clinical relevance and could be inte-
grated into an updated risk profile [13]. However, in 
the same year, the International Chronic Lymphocytic 
Leukemia–International Prognostic Index (CLL-IPI) 
working group created a model which did not include 
other than IGHV and TP53 molecular mutations, 
recognizing the others as showing no independent 
prognostic value. Therefore, there is a need to define 
clinical significance of novel prognostic factors besides 
TP53 and IGHV [14]. 
This review summarizes the available data con-
cerning molecular lesions found in CLL cells with 
a broad reference to their importance for the patho-
genesis of the disease and clinical prognostic value.
TP53
TP53 (tumor protein p53) gene is located on chro-
mosome 17 (17p13.1) and consists of 11 exons and 10 
introns [15]. The translation product of this gene is 
a phosphoprotein with a molecular weight of 53 kDa 
(containing 393 amino acids divided into the three 
domains). It functions as the main tumor suppressor 
in the human cells. The protein is a transcription 
factor composed of typical domains: N-terminal, core 
domain and C-terminal, with specific functions [16]. 
The N-terminal domain contains a region rich in 
prolines residues (proline-rich region, 61–94), made 
up of multiple PXXP motifs (where P is proline and 
X any other amino acid) and also the transactivation 
domain (transactivating domain TAD1 and TAD2, 
amino acids 1–42). Due to this unique domain, TP53 
is responsible for the induction of apoptosis through 
interactions with other proteins while transactiva-
tion of genes is not necessary. Core protein of TP53 
consists mainly of the DNA binding domain (DBD, 
102–292) [17]. C-terminal domain is responsible for 
TP53 tetramerization, non-specific interaction with 
DNA, and has a protein binding site enhancing the 
transcriptional activity of TP53 [18]. The human TP53 
gene expresses 12 different TP53 proteins (isoforms) 
as the effect of alternative splicing [19].
TP53 plays a key role in regulating cell prolifera-
tion, mainly by inducing cell cycle arrest, apoptosis or 
DNA repair mechanisms activation [20]. DNA dam-
age initiates overexpression of TP53 which induces 
a phase G1 arrest providing the integrity of the ge-
nome. Under extensive damage, where DNA cannot 
be repaired, TP53 transactivates genes involved in 
apoptosis. TP53 mutations inhibit the cell cycle arrest 
what causes the deregulation of apoptosis, resulting in 
malignant transformation and proliferation of dam-
aged cells [21]. Loss of TP53 function during tumori-
genesis triggers deregulation of the cell cycle, genetic 
instability and resistance to chemotherapy [22].
Total loss of TP53 function may be caused by co-
existing TP53 mutations with deletion of remaining 
17p allele, mutation of both alleles or homozygous 
mutation resulting from loss of heterozygosity (LOH). 
Another mechanism limiting the functions of TP53 is 
dominant-negative effect: the mutant protein binds 
with the unchanged form, making a complex which is 
incapable of DNA binding and inhibits the transactiva-
tion of other genes. In addition, it is suggested that TP53 
mutations may also change thermodynamic stability of 
proteins and result in the acquisition of new prop-
erties (gain-of-function, GOF) important for tumor 
progression or increasing resistance to treatment [23]. 
The loss of TP53 function due to mutations or dele-
tions is observed in about 50% of solid tumors [24], 
with significantly lower proportion in the case of he-
matological malignancies [25].
TP53 mutations exhibit considerable heterogeneity 
in terms of both structure and location. Approximately 
75% of all mutations represent missense mutations 
leading to amino-acid changes. The vast majority 
of point mutations were found in exons 5 to 8 and 
were clustered in four mutation “hotspots” situated 
between codons 130 and 280. Less frequent are non-
sense mutations, deletions, insertions or mutations in 
transcription sites [26].
Clinically, TP53 alterations are associated with 
inferior prognosis in numerous cancers including 
lymphomas and CLL. Mutations of TP53 are found 
in 10–15% of patients with CLL at diagnosis or before 
first therapy [27–29]. The highest incidence of TP53 
mutations was observed in patients with fludara-
bine-refractory CLL [30]. About 80% of cases with 
17p deletion also hold TP53 mutations in the remain-
ing allele [27, 28]. TP53 mutations in the absence of 
17p deletion concerns 3% of patients in the first-line 
treatment and are associated with significantly worse 
outcome, especially in the case of mutations located in 
the DNA binding domain [29]. Patients with missense 
mutations localized within the DNA-binding motifs 
(DBMs), the parts of DNA binding domains that are 
directly involved in contact with DNA, had largely 
shorter time to first treatment (TFT) and overall 
survival (OS) compared with both remaining missense 
mutations and non-missense alterations [31].
CLL has been found to exhibit TP53 specific 
mutation profiles. Multivariate analysis revealed 
a lower percentage of transitions in CpG sites in CLL 
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compared to other cancers. In addition, transitions 
GÆA were more frequent in comparison with CÆT, 
whereas in the other tumors both changes were at 
a similar level [32].
IGHV
Apart from TP53 mutations, IGHV (immunoglob-
ulin heavy chain variable) gene mutational status is 
well-known prognostic factor for patients with CLL. 
Identification of mutational status of IGHV genes 
was a milestone in understanding CLL biology [33]. 
The presence or absence of mutations in the IGVH 
genes distinguishes two clinical forms of CLL. Patients 
with IGHV mutations display favorable prognosis 
with long OS while group without the mutations are 
characterized by an aggressive course of the disease, 
indicating important role of B-cell receptor (BCR) 
in the pathogenesis of CLL [33, 34]. Additionally, 
approximately 20% of untreated patients exhibit 
almost identical BCR so called stereotyped BCR en-
coded by different, although phylogenetically related 
IGHV genes [35]. The discovery of stereotyped BCR 
enabled to assign almost one-third of CLL patients 
to subsets that represent distinct biological profiles 
determining similar disease course and outcome 
[36]. Malcikova et al. [37] examined the frequency of 
TP53 mutations in relation to IGHV gene status and 
BCR immunoglobulin stereotypy. The study revealed 
a higher percentage of TP53 mutation in the unmu-
tated IGHV group. Additionally, a different profile of 
TP53 mutations in various stereotyped CLL subsets 
was found pointing to different mechanisms respon-
sible for clinical aggressiveness for each subset [37].
Figure 1 exemplifies the different pathogenic 
mechanisms involved in IGHV-mutated and IG-
HV-unmutated CLL.
NOTCH1
The NOTCH1 (neurogenic locus notch homolog pro-
tein 1) gene, encoded on chromosome 9q34.3, plays 
a fundamental biological role in hematopoiesis [9]. 
NOTCH1 receptors have been shown to have an es-
sential role in the pathogenesis of some hematologic 
and solid malignancies [38, 39]. They are a family of 
transmembrane proteins belonging to cell surface 
receptors as well as transcription regulators which 
are expressed by different tissue [40]. 
The extracellular domain of NOTCH1 (N-EC) 
consists of 36 epidermal growth factorlike repeats 
(EGFR), 3 cysteine-rich lin12/Notch repeats (LNR) 
and the heterodimerization domain (HD). In the plas-
ma membrane, NOTCH1 is cleaved in two units, which 
are kept together thanks to interactions between the 
HD domains. After binding to the ligand, NOTCH1 
is further cleaved by the gamma-secretase complex, 
causing release of the intracellular part (N-IC) [41]. 
Subsequently, N-IC can transfer to the nucleus where 
it makes a transcriptional complex. N-IC includes the 
Figure 1. Differential signaling responses in immunoglobulin heavy chain variable (IGHV)-unmutated and mutated chronic 
lymphocytic leukemia (CLL). Figure presents the most important prognostic factors with regard to the IGHV mutational 
status. BIRC3 disrupting mutations and NOTCH1 activating mutations trigger enhanced NF-kB signaling and proliferation 
in IGHV-unmutated CLL. TP53 deletion and/or mutation is more frequent in IGHV-unmutated CLL and results in dys-
functional cell cycle arrest which in consequence leads to enhanced cell survival. ZAP-70 takes part in BcR signaling and 
its overexpression leads to increased cell proliferation through, e.g. NF-kB signaling. Adapted from Rosenquist et al. [99].
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RAM domain (R), ankyrine repeats, transactivation 
domain (TAD) and the PEST sequence that marks 
N-IC for degradation by FBXW7 [42]. PEST region 
plays a main role in the proteasomal degradation of 
the NOTCH receptor by holding to FBXW7, an E3 
ubiquitin ligase, which limits the NOTCH activity. 
Deletion of CT in the C-terminal region leads to 
removal of the PEST domain, shortening NOTCH 
protein, altered NOTCH degradation and continuous 
transcriptional activation of NOTCH target genes 
in CLL, such as MYC, TP53 and molecules of the 
NF-kB (nuclear factor kappa-light-chain-enhancer 
of activated B cells) pathway [10, 43]. Constitutive 
NOTCH1 signaling activation was noticed in CLL cells 
and considered to be involved in apoptosis resistance 
and increased CLL cells survival [38].
NOTCH1 mutation in CLL patients most frequently 
concerns C-terminal PEST domain [44]. At the molec-
ular level, these mutations represent mainly frameshift 
or non-sense events accumulating within exon 34 and 
including recurrent c.7544_7545delCT deletion (around 
80–95% of all mutations) [45]. NOTCH1 mutations in 
CLL interfere with the C-terminal PEST domain of the 
protein, which takes part in the proteasomal degradation 
of the activated form of NOTCH1 [44]. In fact, short 
PEST domain results in stabilization of the active form 
of NOTCH1, the molecule impaired degradation, and 
thus upregulated NOTCH1 signaling [46, 47].
NOTCH1 mutations occur in 5–10% newly diag-
nosed CLL, while their frequency increases to 15–20% 
in progressive CLL requiring first treatment and in 
relapsed cases [45, 48]. NOTCH1 is associated with 
more aggressive clinical presentation of CLL such as 
chemorefractoriness and disease progression towards 
transformation into RS. NOTCH1 mutations in RS 
are the second, after TP53, most frequent genetic le-
sions, where they occur in approximately 30% of cases 
[9, 10, 45]. Analyses on specific and more numerous 
subgroups of patients have revealed a particularly 
high frequency of NOTCH1 mutations in CLL cases 
that harbor trisomy 12 (+12), as the sole cytogenetic 
abnormality (30%) [49]. Moreover, patients with 
NOTCH1 mutations display a significantly shorter 
overall survival refining the intermediate prognosis 
of CLL patients with +12. Importantly, the high fre-
quency of NOTCH1 mutations in +12 (trisomy 12) 
CLL patients is associated with a characteristic 
gene-expression profile characterized by an overex-
pression of cell cycle related genes located on chro-
mosome 12 [49]. Balatti et al. revealed that NOTCH1 
mutations were enriched among IGHV-unmutated/
ZAP70+ CLL patients harboring +12 (about 42%), 
as compared to much lower presence in 4% of IGHV- 
-unmutated/ZAP70+ cases without +12 [50].
NOTCH1 mutations may constitute potential new 
biomarker for the selection of poor-risk CLL patients. 
Patients with NOTCH1 mutations are characterized 
by a significantly shorter OS (21–45% at 10 years) and 
present a more rapidly progressive disease compared 
to NOTCH1 wild-type cases (56–66% at 10 years) [9, 
10, 45]. According to Mansouri et al., NOTCH1 muta-
tions similarly as TP53 mutations seem to be strong, in-
dependent prognostic markers of poor prognosis [51]. 
In the United Kingdom Leukaemia Research Fund 
Chronic Lymphocytic Leukemia 4 (UK LRF CLL 
4) trial study [48] patients with NOTCH1 mutations 
had significantly shorter OS compared to wild-type 
cases (respectively 55 and 83 months) but longer than 
patients carrying TP53 abnormalities (26 months). 
The short OS related to NOTCH1 mutations could 
be in part explained by a significantly higher risk 
(45% in NOTCH1 mutated vs. 4.6% in wild-types) 
of developing RS in patients harboring NOTCH1 
aberrations [52]. On the basis of preliminary German 
CLL Study Group (GCLLSG) CLL8 trial exploring 
the role of new mutations in CLL patients treated 
with first-line fludarabine-cyclophosphamide (FC) 
or fludarabine-cyclophosphamide-rituximab (FCR), 
NOTCH1 mutations constitute independent predic-
tors of short progression-free survival (PFS) even after 
FCR treatment [53]. On the contrary, data from the 
GCLLSG CLL2H trial determining the incidences, 
associations, and prognostic roles of NOTCH1, SF3B1 
and TP53 mutations in fludarabine-refractory CLL 
patients treated with alemtuzumab indicate that 
patients with NOTCH1 mutations may have longer 
PFS after treatment with alemtuzumab compared 
to NOTCH1 wild-type settings [54]. In multivariable 
analyses, NOTCH1 mutations was identified as an 
independent favorable marker for PFS [55].
SF3B1
The SF3B1 (splicing factor 3b subunit 1) protein is 
the product of the same-named gene which is com-
posed of 25 exons and located on chromosome 2 in 
q33.1 region [56]. The protein is considered to be an 
essential component of the splicing machinery in the 
process of RNA editing. Splicing consists of the stages 
of removing introns, which are noncoding sequences, 
from premessenger RNA and ligating the remaining 
exons together. The product of SF3B1 gene is involved 
in the control of connecting the premessenger RNA 
with macromolecule, spliceosome, at the beginning 
of the process. Two types of spliceosome are known: 
U2-dependent type (classical) and U12 type (alterna-
tive), of which each one is composed of five unique 
nucleoproteins RNA (snRNPs) [57]. SF3B1 is the 
core protein of snRNP in classical spliceosome. Its 
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role is to recognize the branch side of premRNA, 
and, subsequently, to bind it with the spliceosome, 
what is the initial stadium of splicing [57, 58]. The 
abnormalities of this regulation, which are associ-
ated with the mutations in SF3B1 gene, may lead 
to unintended introns retention, and, consequently, 
to forming alternative, modified transcripts [59]. In 
the structure of the SF3B1 protein there are two key 
regions. The first of them is N-terminal end which 
contains a few binding factors to interact with other 
spliceosome components forming the complex. The 
second one is C-terminal end with 22 tandem-repeat 
domains including HEAT (Huntingtin, Elongation 
factor 3, protein phosphatase 2A, Targets of rapamy-
cin 1) motifs. The precise role of C-terminus is still 
unknown [11, 60]. C-terminal HEAT repeats interfere 
alternatively with U2 snRNP and other spliceosomal 
components what might regulate splicing activity [61].
In the last years, it becomes evident that mutations 
in SF3B1 gene are connected with pathogenesis of he-
matological disorders, especially with myelodysplastic 
syndrome [62] and CLL. SF3B1 mutations in CLL are 
generally represented by missense substitutions affect-
ing the HEAT domains of the SF3B1 protein. Most 
of them are detectable between the fifth to the eighth 
HEAT repeats (encoded by exons 14–16). The main 
target, accounting for approximately 40% to 50% of 
all SF3B1 mutations, are five hotspots (codons 662, 
666, 700, 704 and 742), with the K700E substitution 
[61, 63–66]. The second most common substitution 
is G742D (19%), a mutation rarely found in myeloid 
neoplasm [11, 63].
The role of SF3B1 mutations at the cellular level 
remains unknown [67]. Possibly, modified product 
of the mutated gene interacts incorrectly with RNA 
and cofactors. However, the small amount of al-
tered transcripts indicates that the mutations do not 
influence the mechanism of splicing globally [68]. 
Perhaps, the alternative splicing is the consequence 
of the mutation, which, in fact, does not influence 
the pathogenesis of the disease. The recent studies 
suggest that the mutation results in anomaly of the 
response to the DNA damage what disturbs genomic 
stability [65, 66]. Other cellular functions that might be 
deregulated are telomere maintenance and NOTCH 
signaling in CLL cells [67].
The SF3B1 mutations may be subclonal, which 
is the conclusion of the frequency and the time of 
their occurrence in comparison with other defects 
in CLL known as drive mutations (MYD88, trisomy 
12, del13q). In the study of Landau et al. [69], it was 
disclosed that drive mutations occur in the earlier 
stage of the CLL and among higher percentage of 
patients. The incidence of SF3B1 mutations appears 
to increase over time and they are correlated with 
a more advanced clinical stage. Therefore, the SF3B1 
mutations should be taken into account as an impor-
tant marker of the disease progression or even one 
of its mechanisms [70]. 
In the studies conducted by a few research groups 
SF3B1 mutations have been observed in CLL cells 
with frequency accounting from 5 to 20%. Further-
more, it was noticed that SF3B1 mutations recur 
rarely in newly diagnosed CLL (5%), while more often 
(15%) in progressive CLL requiring first treatment 
and even in 20% relapsed and chemorefractory pa-
tients [11, 60, 65, 71, 72]. Consequently, the presence 
of the SF3B1 mutations in the CLL cells is concerned 
with less favorable prognosis. Patients with SF3B1 
mutations were characterized by significantly shorter 
time to treatment, short PFS after treatment and also 
low OS rate [65, 73]. Moreover, SF3B1 mutations are 
associated with chemoresistance to alkylating agents 
and fludarabine therapy [71, 73]. The mutations do 
not limit the survival after allogenetic hematopoietic 
stem cell transplantation (HSCT),which means it 
influences negligibly the long term disease control 
of HSCT [74]. Some correlations between SF3B1 
mutations and other lesions have been described in 
CLL. It was noticed that SF3B1 mutations occur more 
frequently in association with 11q22-q23 deletion, 
ATM mutations and unmutated IGHV status while 
negative correlation was observed with trisomy 12 
and isolated del13q [68, 70]. The assessment of SF3B1 
mutation status may contribute to the identification 
of poor-risk CLL patients and in combination with 
conventional lesions of CLL may refine the disease 
prognosis [62, 68].
BIRC3
Baculoviral IAP repeat-containing protein 3 (BIRC3) 
belongs to the members of the IAP (inhibitor of 
apoptosis) family which was firstly described in the 
virus-infected cells. BIRC3 is encoded by gene lo-
cated in chromosome 11 (11q22.2) and composed of 
602 amino acids [75]. In adults it is mainly expressed 
in lymphoid tissue, especially spleen, and peripheral 
blood lymphocytes. The structure of BIRC3 protein 
is characterized by specific motif, zinc finger do-
main, containing zinc ions coordinated by cysteine 
and histidine residues. The second specific region is 
caspase-recruitment domain (CARD) which is com-
monly found in proteins involved in inflammation 
process. Furthermore, BIRC3 protein has three BIR 
repeats [76, 77].
The basic and earliest known function of BIRC3 
and other IAPs is the regulation of cellular signal 
pathways controlling the process of apoptosis. They 
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are responsible for the inhibition of the proteolytic 
activities of caspases — proteases required for in-
tracellular protein degradation and execution of cell 
necrosis. The inhibition of apoptosis is achieved by 
ubiquitination of caspases 3 and 7, deactivation of 
pro-caspase 9 and preventing cell death induced by 
Fas ligand [78]. The independent ubiquitin ligase 
activity is attributed to the zinc finger domain [79]. 
The BIR motifs region participates in interaction 
between BIRC3 and tumor necrosis factor (TNF) 
receptor-associated factors (TRAF1, TRAF2). This 
formed complex regulates negatively MAP3K14 
serine-threonine kinase, the central activator of 
non-canonical NF-kB signaling. Consequently, BIRC3 
prevents from overactivation of NF-kB which might 
result in uncontrolled transcription [80, 81]. Inter-
action with TRAFs is required to ubiquitinate the 
inhibitor of nuclear factor kappa-B kinase (IKK2), 
degradation of NF-kB inhibitor alpha (IkBa) and, 
finally, activation of NF-kB. Taken together, the role 
of BIRC3 in the regulation of NF-kB signaling is dual: 
stimulatory and inhibitory [63, 81, 82]. Moreover, 
BIRC3 prevents NF-kB-mediated transcriptional and 
posttranslational modifications of MDM2 disrupting 
its expression and function. 
Recently, it has been observed that BIRC3 protein 
plays a role in modulation of inflammatory signaling 
and immunological processes, which confirms its 
multifunctional character. Mutations in BIRC3 might 
be represented by a single gene disruption or com-
bination of two of them. Most of them are deletions, 
frameshift disorders and nonsense substitutions, re-
sulting in inactivation of BIRC3 protein [63]. It is the 
result either of reduced transcription of the deleted 
gene or loss of function due to cutoff of its C-termi-
nal zing finger domain. Truncation of this specific 
domain, which is characterized by ubiquitin ligase 
activity, excludes the BIRC3 protein from inhibition of 
non-canonical NF-kB signaling [83]. Clear functional 
effect of the mutation in BIRC3 gene is, therefore, 
permanent activation of NF-kB [63, 84].
The molecular alterations targeting BIRC3 gene 
should be considered as novel important prognos-
tic parameter in CLL. According to classification 
proposed by Rossi et al. [12], the BIRC3 alterations 
were associated with high-risk disease, where the 
estimated 10-years survival was 29%. Furthermore, 
in retrospective analysis the median OS was compa-
rable to patients with TP53 abnormalities and reached 
3 years [12]. Consequently, the BIRC3 mutation is 
associated with shorter PFS and OS [12, 63, 85]. 
There are reports which attribute the presence of the 
mutation to chemorefractoriness [83, 86, 87]. In the 
study of Landau et al. [86], 24% of patients who were 
refractory to fludarabine-therapy harbored mutated 
BIRC3 gene. BIRC3 mutations are rarely described 
in patients at diagnosis of CLL accounting from 2 to 
10% [85–88]. They might be detected between exons 
2 and 9 [87]. Interestingly, they occur mainly within 
11q22-q23 deletions (49% in the study by Del Poeta et 
al. [85]). It has been suggested that poor outcome of 
CLL depends not on the BIRC3 disruption but on the 
concomitant del11q or ATM mutation [83, 84]. Cer-
tainly, the functional consequence of the mutations in 
BIRC3 gene and their implications for the diagnosis in 
the patients with CLL should remain under scrutiny. 
MYD88
Myeloid differentiation primary response 88 (MYD88) 
is a protein that plays an essential role in the innate 
and adaptive immune response and is encoded by the 
MYD88 gene which is located on the short (p) arm 
of chromosome 3 at position 22 (3p22) [89]. MYD88 
functions as a signaling adaptor protein that activates 
the NF-kB pathway after stimulation of toll-like re-
ceptors (TLRs) and receptors for IL-1 and IL-18 on 
dependent and independent signaling pathways [90]. 
Furthermore, MYD88 coordinates the gathering of 
a multi-subunit signaling complex which consists of 
various members of the IRAK family of serine-thre-
onine kinases [91].
Ngo et al. found mutations in MYD88 in 39% 
of cases of activated B cell type diffuse large B cell 
lymphoma (ABC-DLBCL), with a single L265P sub-
stitution accounting for 75% of the mutations [92]. 
The L265P mutation occurs in almost 100% of cases of 
Waldenström’s macroglobulinemia [93], and 2–10% 
of cases of CLL [10, 94]. Other Toll/IL-1R like domain 
mutations, such as S219C, prevail in germinal center 
B cell type diffuse large B cell lymphoma (GCB-DL-
BCL) [92].
The most common mutation is a single-nucleotide 
change (c.794T.C) that results in a switch of leucine to 
proline at codon 265 (p.L265P) [94]. That predomi-
nant mutation leads to constitutive NF-kB stimulation, 
thus conferring a proliferation and survival advantage 
to the mutant cells. MYD88 mutations reach up 2% 
to 5% in CLL and are strikingly enriched among pa-
tients expressing mutated IGHV genes (M-CLL) [88]. 
Baliakas et al. [70] studied the clinical significance 
of MYD88 mutations in a collaborative multicenter 
series of 1039 well-annotated CLL cases. In this re-
search MYD88 mutations were identified in 24/1080 
(2.2%) CLL patients and 92% cases implemented 
the hotspot p.L265P substitution. In Xia et al. [88] 
study on Chinese population with CLL, mutations in 
exons 3-5 of MYD88 were detected in 23 (8%) of 295 
analyzed cases. These mutations were more common 
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Table 1. Detailed description of TP53, NOTCH1, SF3B1, MYD88 and BIRC3 mutations in CLL patients
Gene Nucleotide change, 
% of mutation
Amino acid 
change
Exon (domain) Evaluation method References
TP53 p.R158H
p.H193L
p.H214R
p.R249W
p.G245S
p.P278A
p.Q317X
c.473G>A
c.578A>T
c.641A>G
c.745A>T
c.733G>A
c.832C>G
c.949C>T
4–9 — Sanger sequencing
— NGS 
— dHPLC
— FASAY
— Arrays (Affymetrix/Roche GeneChip Arrays 
and p53 AmpliChip)
[96, 97]
SF3B1 K700E, 50%
p.G742D, 19%
K666E, 12%
H662Q, 4%
H662D, 4%
c.2146A>G
c.2273G>A
c.2044A>G
c.1984C>G
c.1986C>G
14–16 (HEAT) — Sanger sequencing [87, 88]
NOTCH1 c.7544_7545delCT, 
80–95%
p.P2515fs 34 (PEST) — ARMS PCR 
— Sanger sequencing
[11, 87, 88]
BIRC3 c.1673_1674del2bp
c.1586A>T
p.K558fs
p.Q529L
6–9 (RING, 
CARD)
— Sanger sequencing [87]
MYD88
 
p.L265P, 3.2% c.794T>C 5 — ARMS PCR
— Sanger sequencing
— NGS
[88, 92]
Abbreviations: ARMS PCR — amplification refractory mutation system; CLL — chronic lymphocytic leukemia; dHPLC — denaturing high perfor-
mance liquid chromatography; FASAY — functional analysis of separated alleles in yeast; NGS — next generation sequencing.
Figure 2. Association between novel gene mutations and established prognostic factors in chronic lymphocytic leukemia 
(CLL) patients. Graph prepared using Circos program [98]. Circos plots show the pairwise co-occurrence of gene mutations 
with cytogenetic status, of immunoglobulin heavy chain variable (IGHV) mutational status and expression of CD38 and 
ZAP-70. The length of the arc corresponds to the frequency of the mutations. The width of the ribbon corresponds to the 
proportion of co-occurrence with the second marker. 
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in patients with mutated IGHV (2 of 115 vs. 21 of 
172; p = 0.001). In the other study Jeromin et al. [95] 
analyzed a large cohort of 1160 untreated CLL pa-
tients for novel genetic markers including MYD88. 
The mutation was found in 15/969 cases (1.5%) and 
it was associated with mutated IGHV status.
Detailed description of the most frequent novel 
mutations in CLL and methods of their analysis are 
summarized in Table 1. Association between novel 
gene mutations and clinico-biological features of CLL 
patients present Figure 2 and Table 2.
Summary
Taking into account the clinical heterogeneity in CLL 
patients, there has been a great need to find novel 
genetic markers that could improve prognostication. 
Precise risk profile based on new mutations might 
contribute to more personalized strategy of treatment 
and modification of therapeutic algorithms focusing 
on earlier intervention in patients from high-risk 
groups. Rossi et al. [12] settled that the most accu-
rate survival prediction is achieved by integrating 
mutational and cytogenetic analyses. On this basis, 
a hierarchical model consisting of four subgroups was 
identified, which classifies the patients as follows: (1) 
high-risk, harboring TP53 and/or BIRC3 abnormal-
ities (10-year survival: 29%); (2) intermediate-risk, 
harboring NOTCH1 and/or SF3B1 mutations and/or 
del11q22-q23 (10-year survival: 37%); (3) low-risk, 
harboring +12 or a normal karyotype (10-year sur-
vival: 57%); and (4) very low-risk, harboring del13q14 
only, whose 10-year survival (69.3%) did not signifi-
cantly differ from a general population. Meanwhile, 
the International Prognostic Index for CLL (CLL-IPI) 
from 2016, has integrated only the IGHV mutational 
status and TP53 aberrations [14]. TP53 constitutes 
the only biomarker in CLL that currently guides 
treatment decisions. Other novel mutations such as 
NOTCH1, SF3B1 and BIRC3 do not guide therapeu-
tic choices. Nevertheless, they constitute markers of 
unfavorable prognosis of CLL, rapid progression and 
shorter OS [96].
Acknowledgments
This work was supported by Medical University of 
Lublin Scientific Grant MNmb 537.
References
1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leu-
kemia. N Engl J Med. 2005; 352(8): 804–815, doi: 10.1056/
NEJMra041720, indexed in Pubmed: 15728813.
2. Abrisqueta P, Pereira A, Rozman C, et al. Improving survival 
in patients with chronic lymphocytic leukemia (1980-2008): 
the Hospital Clinic of Barcelona experience. Blood. 2009; 
114(10): 2044–2050, doi: 10.1182/blood-2009-04-214346, in-
dexed in Pubmed: 19553638.
3. Shanafelt TD, Jenkins G, Call TG, et al. Validation of 
a new prognostic index for patients with chronic lymphocyt-
ic leukemia. Cancer. 2009; 115(2): 363–372, doi: 10.1002/ 
cncr.24004, indexed in Pubmed: 19090008.
4. Hallek M, Cheson BD, Catovsky D, et al. International 
Workshop on Chronic Lymphocytic Leukemia. Guidelines 
for the diagnosis and treatment of chronic lymphocytic leu-
kemia: a report from the International Workshop on Chronic 
Lymphocytic Leukemia updating the National Cancer Insti-
tute-Working Group 1996 guidelines. Blood. 2008; 111(12): 
5446–5456, doi: 10.1182/blood-2007-06-093906, indexed in 
Pubmed: 18216293.
5. Dighiero G, Hamblin TJ. Chronic lymphocytic leukaemia. 
Lancet. 2008; 371(9617): 1017–1029, doi: 10.1016/S0140-
6736(08)60456-0, indexed in Pubmed: 18358929.
6. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared 
with immunoglobulin heavy-chain gene mutation status as 
a predictor of disease progression in chronic lymphocytic leu-
kemia. N Engl J Med. 2004; 351(9): 893–901, doi: 10.1056/ 
NEJMoa040857, indexed in Pubmed: 15329427.
Table 2. Detailed characteristic of novel genetic mutations in chronic lymphotic leukemia patients
Prognostic factors Percentage of CLL patients expressing gene mutations
SF3B1 NOTCH1 MYD88 TP53 BIRC3
IGHV-M 54/202 (26.7%)70 2/26 (4%)87 19/21 (90%)95 5/17 (25%)87 5/23 (21.7%)70
IGHV-UM 148/202 (73.3%)70 24/26 (96%)87 2/21 (10%)95 12/17 (75%)87 18/23 (78.3%)70
Del 13q 78/243 (32.1%)70 7/26 (26%)87 12/18 (67%)95 2/17 (12%)87 2/23 (8.7%)70
Trisomy 12 15/245 (6.1%)70 10/26 (38%)87 2/17 (12%)95 087 10/23 (43.5%)70
Del 11q 67/245 (27.3%)70 3/26 (12%)87 2/18 (6%)95 087 11/23 (47.8%)70
Del 17p 14/246 (5.7%)70 3/26 (12%)87 1/18 (6%)95 14/17 (82%)87 0/23 (0%)70
ZAP-70+ 7/110 (6.4%)88 20/26 (80%)87 6/106 (6%)88 7/17 (47%)87 10/14 (71.4%)87
CD38+ 5/71 (7%)88 20/26 (77%)87 1/67 (2%)88 7/17 (44%)87 7/14 (50%)87
Superscripts denote references in the main text.
103Novel prognostic molecular factors: a quantum leap in chronic lymphocytic leukemia
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2017
10.5603/FHC.a2017.0019
www.fhc.viamedica.pl
7. Döhner H, Stilgenbauer S, Benner A, et al. Genomic ab-
errations and survival in chronic lymphocytic leukemia. 
N Engl J Med. 2000; 343(26): 1910–1916, doi: 10.1056/
NEJM200012283432602, indexed in Pubmed: 11136261.
8. Foà R, Del Giudice I, Guarini A, et al. Clinical implications 
of the molecular genetics of chronic lymphocytic leukemia. 
Haematologica. 2013; 98(5): 675–685, doi: 10.3324/haema-
tol.2012.069369, indexed in Pubmed: 23633543.
9. Fabbri G, Rasi S, Rossi D, et al. Analysis of the chronic lym-
phocytic leukemia coding genome: role of NOTCH1 muta-
tional activation. J Exp Med. 2011; 208(7): 1389–1401, doi: 
10.1084/jem.20110921, indexed in Pubmed: 21670202.
10. Puente XS, Pinyol M, Quesada V, et al. Whole-genome se-
quencing identifies recurrent mutations in chronic lymphocyt-
ic leukaemia. Nature. 2011; 475(7354): 101–105, doi: 10.1038/ 
nature10113, indexed in Pubmed: 21642962.
11. Quesada V, Conde L, Villamor N, et al. Exome sequencing 
identifies recurrent mutations of the splicing factor SF3B1 
gene in chronic lymphocytic leukemia. Nat Genet. 2011; 44(1): 
47–52, doi: 10.1038/ng.1032, indexed in Pubmed: 22158541.
12. Rossi D, Rasi S, Spina V, et al. Integrated mutational and 
cytogenetic analysis identifies new prognostic subgroups in 
chronic lymphocytic leukemia. Blood. 2013; 121(8): 1403–
–1412, doi: 10.1182/blood-2012-09-458265, indexed in Pub-
med: 23243274.
13. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision 
of the World Health Organization classification of lymphoid 
neoplasms. Blood. 2016; 127(20): 2375–2390, doi: 10.1182/ 
blood-2016-01-643569, indexed in Pubmed: 26980727.
14. International CLL-IPI working group. An international 
prognostic index for patients with chronic lymphocytic leu-
kaemia (CLL-IPI): a meta-analysis of individual patient data. 
Lancet Oncol. 2016; 17(6): 779–790, doi: 10.1016/S1470-
2045(16)30029-8, indexed in Pubmed: 27185642.
15. Lamb P, Crawford L. Characterization of the human p53 
gene. Mol Cell Biol. 1986; 6(5): 1379–1385, doi: 10.1128/ 
mcb.6.5.1379.
16. Yang A, Kaghad M, Wang Y, et al. p63, a p53 homolog at 
3q27-29, encodes multiple products with transactivating, 
death-inducing, and dominant-negative activities. Mol Cell. 
1998; 2(3): 305–316, doi: 10.1016/s1097-2765(00)80275-0, in-
dexed in Pubmed: 9774969.
17. Venot C, Maratrat M, Dureuil C, et al. The requirement for 
the p53 proline-rich functional domain for mediation of apop-
tosis is correlated with specific PIG3 gene transactivation and 
with transcriptional repression. EMBO J. 1998; 17(16): 4668–
–4679, doi: 10.1093/emboj/17.16.4668, indexed in Pubmed: 
9707426.
18. Laptenko O, Shiff I, Freed-Pastor W, et al. The p53 C termi-
nus controls site-specific DNA binding and promotes structur-
al changes within the central DNA binding domain. Mol Cell. 
2015; 57(6): 1034–1046, doi: 10.1016/j.molcel.2015.02.015, 
indexed in Pubmed: 25794615.
19. Khoury MP, Bourdon JC. p53 isoforms: an intracellular 
microprocessor? Genes Cancer. 2011; 2(4): 453–465, doi: 
10.1177/1947601911408893, indexed in Pubmed: 21779513.
20. Bieging KT, Mello SS, Attardi LD. Unravelling mechanisms 
of p53-mediated tumour suppression. Nat Rev Cancer. 2014; 
14(5): 359–370, doi: 10.1038/nrc3711, indexed in Pubmed: 
24739573.
21. Xu-Monette ZY, Medeiros LJ, Li Y, et al. Dysfunction of the 
TP53 tumor suppressor gene in lymphoid malignancies. Blood. 
2012; 119(16): 3668–3683, doi: 10.1182/blood-2011-11-366062, 
indexed in Pubmed: 22275381.
22. Velletri T, Xie N, Wang Y, et al. P53 functional abnormality 
in mesenchymal stem cells promotes osteosarcoma devel-
opment. Cell Death Dis. 2016; 7: e2015, doi: 10.1038/cd-
dis.2015.367, indexed in Pubmed: 26775693.
23. Oren M, Rotter V. Mutant p53 gain-of-function in cancer. 
Cold Spring Harb Perspect Biol. 2010; 2(2): a001107, doi: 
10.1101/cshperspect.a001107, indexed in Pubmed: 20182618.
24. Soussi T, Dehouche K, Béroud C. p53 website and analy-
sis of p53 gene mutations in human cancer: forging 
a link between epidemiology and carcinogenesis. Hum 
Mutat. 2000; 15(1): 105–113, doi: 10.1002/(SICI)1098-
1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G, in-
dexed in Pubmed: 10612830.
25. Pekova S, Mazal O, Cmejla R, et al. A comprehensive study 
of TP53 mutations in chronic lymphocytic leukemia: Analy-
sis of 1287 diagnostic and 1148 follow-up CLL samples. Leuk 
Res. 2011; 35(7): 889–898, doi: 10.1016/j.leukres.2010.12.016, 
indexed in Pubmed: 21232794.
26. Rücker FG, Schlenk RF, Bullinger L, et al. TP53 alterations 
in acute myeloid leukemia with complex karyotype correlate 
with specific copy number alterations, monosomal karyotype, 
and dismal outcome. Blood. 2012; 119(9): 2114–2121, doi: 
10.1182/blood-2011-08-375758, indexed in Pubmed: 22186996.
27. Rossi D, Cerri M, Deambrogi C, et al. The prognostic value 
of TP53 mutations in chronic lymphocytic leukemia is independ-
ent of Del17p13: implications for overall survival and chemore-
fractoriness. Clin Cancer Res. 2009; 15(3): 995–1004, doi: 
10.1158/1078-0432.CCR-08-1630, indexed in Pubmed: 19188171.
28. Dicker F, Herholz H, Schnittger S, et al. The detection 
of TP53 mutations in chronic lymphocytic leukemia inde-
pendently predicts rapid disease progression and is highly 
correlated with a complex aberrant karyotype. Leukemia. 
2009; 23(1): 117–124, doi: 10.1038/leu.2008.274, indexed in 
Pubmed: 18843282.
29. Gonzalez D, Martinez P, Wade R, et al. Mutational status 
of the TP53 gene as a predictor of response and survival in 
patients with chronic lymphocytic leukemia: results from the 
LRF CLL4 trial. J Clin Oncol. 2011; 29(16): 2223–2229, doi: 
10.1200/JCO.2010.32.0838, indexed in Pubmed: 21483000.
30. Zenz T, Häbe S, Denzel T, et al. Detailed analysis of p53 
pathway defects in fludarabine-refractory chronic lymphocytic 
leukemia (CLL): dissecting the contribution of 17p deletion, 
TP53 mutation, p53-p21 dysfunction, and miR34a in a pro-
spective clinical trial. Blood. 2009; 114(13): 2589–2597, doi: 
10.1182/blood-2009-05-224071, indexed in Pubmed: 19643983.
31. Malcikova J, Pavlova S, Kozubik KS, et al. TP53 mutation 
analysis in clinical practice: lessons from chronic lymphocyt-
ic leukemia. Hum Mutat. 2014; 35(6): 663–671, doi: 10.1002/ 
humu.22508, indexed in Pubmed: 24415659.
32. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 
functional properties on TP53 mutation patterns and tumor 
phenotype: lessons from recent developments in the IARC 
TP53 database. Hum Mutat. 2007; 28(6): 622–629, doi: 
10.1002/humu.20495, indexed in Pubmed: 17311302.
33. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) 
genes are associated with a more aggressive form of chronic 
lymphocytic leukemia. Blood. 1999; 94(6): 1848–1854, indexed 
in Pubmed: 10477713.
34. Langerak AW, Davi F, Ghia P, et al. European Research 
Initiative on CLL (ERIC). Immunoglobulin sequence anal-
ysis and prognostication in CLL: guidelines from the ERIC 
review board for reliable interpretation of problematic cases. 
Leukemia. 2011; 25(6): 979–984, doi: 10.1038/leu.2011.49, 
indexed in Pubmed: 21455216.
104 Ewelina Zakrzewska et al.
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2017
10.5603/FHC.a2017.0019
www.fhc.viamedica.pl
35. Cesano A, Perbellini O, Evensen E, et al. Association be-
tween B-cell receptor responsiveness and disease progres-
sion in B-cell chronic lymphocytic leukemia: results from 
single cell network profiling studies. Haematologica. 2013; 
98(4): 626–634, doi: 10.3324/haematol.2012.071910, indexed 
in Pubmed: 23144194.
36. Stamatopoulos K, Agathangelidis A, Rosenquist R, et al. An-
tigen receptor stereotypy in chronic lymphocytic leukemia. 
Leukemia. 2016; 31(2): 282–291, doi: 10.1038/leu.2016.322.
37. Malcikova J, Stalika E, Davis Z, et al. The frequency of TP53 
gene defects differs between chronic lymphocytic leukaemia 
subgroups harbouring distinct antigen receptors. Br J Hae-
matol. 2014; 166(4): 621–625, doi: 10.1111/bjh.12893, indexed 
in Pubmed: 24725250.
38. Rosati E, Sabatini R, Rampino G, et al. Constitutively acti-
vated Notch signaling is involved in survival and apoptosis 
resistance of B-CLL cells. Blood. 2009; 113(4): 856–865, doi: 
10.1182/blood-2008-02-139725, indexed in Pubmed: 18796623.
39. Hajdu M, Sebestyén A, Barna G, et al. Activity of the 
notch-signalling pathway in circulating human chronic lym-
phocytic leukaemia cells. Scand J Immunol. 2007; 65(3): 
271–275, doi: 10.1111/j.1365-3083.2006.01897.x, indexed in 
Pubmed: 17309782.
40. Leong KG, Karsan A. Recent insights into the role of Notch 
signaling in tumorigenesis. Blood. 2006; 107(6): 2223–2233, 
doi: 10.1182/blood-2005-08-3329, indexed in Pubmed: 
16291593.
41. Sanchez-Irizarry C, Carpenter AC, Weng AP, et al. Notch 
subunit heterodimerization and prevention of ligand-inde-
pendent proteolytic activation depend, respectively, on a novel 
domain and the LNR repeats. Mol Cell Biol. 2004; 24(21): 
9265–9273, doi: 10.1128/MCB.24.21.9265-9273.2004, indexed 
in Pubmed: 15485896.
42. Gianfelici V. Activation of the NOTCH1 pathway in chronic 
lymphocytic leukemia. Haematologica. 2012; 97(3): 328–330, 
doi: 10.3324/haematol.2012.061721, indexed in Pubmed: 
22383743.
43. Lobry C, Oh P, Aifantis I. Oncogenic and tumor suppres-
sor functions of Notch in cancer: it’s NOTCH what you 
think. J Exp Med. 2011; 208(10): 1931–1935, doi: 10.1084/ 
jem.20111855, indexed in Pubmed: 21948802.
44. Di Ianni M, Baldoni S, Rosati E, et al. A new genetic lesion in 
B-CLL: a NOTCH1 PEST domain mutation. Br J Haematol. 
2009; 146(6): 689–691, doi: 10.1111/j.1365-2141.2009.07816.x, 
indexed in Pubmed: 19604236.
45. Rossi D, Rasi S, Fabbri G, et al. Mutations of NOTCH1 
are an independent predictor of survival in chronic lympho-
cytic leukemia. Blood. 2011; 119(2): 521–529, doi: 10.1182/ 
blood-2011-09-379966.
46. Paganin M, Ferrando A. Molecular pathogenesis and target-
ed therapies for NOTCH1-induced T-cell acute lymphoblas-
tic leukemia. Blood Rev. 2011; 25(2): 83–90, doi: 10.1016/j.
blre.2010.09.004, indexed in Pubmed: 20965628.
47. Pear WS, Aster JC. T cell acute lymphoblastic leukemia/ 
lymphoma: a human cancer commonly associated with aber-
rant NOTCH1 signaling. Curr Opin Hematol. 2004; 11(6): 
426–433, doi: 10.1097/01.moh.0000143965.90813.70, indexed 
in Pubmed: 15548998.
48. Rose-Zerilli MJJ, Forster J, Parker H, et al. The clinical 
significance of NOTCH1 and SF3B1 mutations in the UK 
LRF CLL4 trial. Blood. 2013; 121(3): 468–475, doi: 10.1182/
blood-2012-05-429282, indexed in Pubmed: 23086750.
49. Del Giudice I, Rossi D, Chiaretti S, et al. NOTCH1 muta-
tions in +12 chronic lymphocytic leukemia (CLL) confer an 
unfavorable prognosis, induce a distinctive transcriptional 
profiling and refine the intermediate prognosis of +12 CLL. 
Haematologica. 2012; 97(3): 437–441, doi: 10.3324/haema-
tol.2011.060129, indexed in Pubmed: 22207691.
50. Balatti V, Bottoni A, Palamarchuk A, et al. NOTCH1 muta-
tions in CLL associated with trisomy 12. Blood. 2012; 119(2): 
329–331, doi: 10.1182/blood-2011-10-386144, indexed in Pub-
med: 22086416.
51. Mansouri L, Cahill N, Gunnarsson R, et al. NOTCH1 and 
SF3B1 mutations can be added to the hierarchical prognos-
tic classification in chronic lymphocytic leukemia. Leukemia. 
2013; 27(2): 512–514, doi: 10.1038/leu.2012.307, indexed in 
Pubmed: 23138133.
52. Rossi D, Rasi S, Spina V, et al. Different impact of NOTCH1 
and SF3B1 mutations on the risk of chronic lymphocytic leu-
kemia transformation to Richter syndrome. Br J Haematol. 
2012; 158(3): 426–429, doi: 10.1111/j.1365-2141.2012.09155.x, 
indexed in Pubmed: 22571487.
53. Stilgenbauer S, Schnaiter A, Paschka P, et al. Gene muta-
tions and treatment outcome in chronic lymphocytic leu-
kemia: results from the CLL8 trial. Blood. 2014; 123(21): 
3247–3254, doi: 10.1182/blood-2014-01-546150, indexed in 
Pubmed: 24652989.
54. Stilgenbauer S, Zenz T, Winkler D, et al. German Chron-
ic Lymphocytic Leukemia Study Group. Subcutaneous 
alemtuzumab in fludarabine-refractory chronic lymphocytic 
leukemia: clinical results and prognostic marker analyses 
from the CLL2H study of the German Chronic Lympho-
cytic Leukemia Study Group. J Clin Oncol. 2009; 27(24): 
3994–4001, doi: 10.1200/JCO.2008.21.1128, indexed in Pub-
med: 19597025.
55. Schnaiter A, Paschka P, Rossi M, et al. NOTCH1, SF3B1, 
and TP53 mutations in fludarabine-refractory CLL patients 
treated with alemtuzumab: results from the CLL2H trial of 
the GCLLSG. Blood. 2013; 122(7): 1266–1270, doi: 10.1182/ 
blood-2013-03-488197, indexed in Pubmed: 23821658.
56. National Center for Biotechnology Information resources. 
SF3B1 splicing factor 3b subunit 1 [Homo sapiens(human)]. 
https://www.ncbi.nlm.nih.gov/gene/23451 (September 27, 
2017).
57. Wahl MC, Will CL, Lührmann R. The spliceosome: design 
principles of a dynamic RNP machine. Cell. 2009; 136(4): 
701–718, doi: 10.1016/j.cell.2009.02.009, indexed in Pubmed: 
19239890.
58. Cazzola M, Rossi M, Malcovati L, et al. Associazione Italiana 
per la Ricerca sul Cancro Gruppo Italiano Malattie Mielopro-
liferative. Biologic and clinical significance of somatic muta-
tions of SF3B1 in myeloid and lymphoid neoplasms. Blood. 
2013; 121(2): 260–269, doi: 10.1182/blood-2012-09-399725, 
indexed in Pubmed: 23160465.
59. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway 
mutations of splicing machinery in myelodysplasia. Nature. 
2011; 478(7367): 64–69, doi: 10.1038/nature10496, indexed 
in Pubmed: 21909114.
60. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel 
cancer genes in chronic lymphocytic leukemia. N Engl J Med. 
2011; 365(26): 2497–2506, doi: 10.1056/NEJMoa1109016, in-
dexed in Pubmed: 22150006.
61. Tang Q, Rodriguez-Santiago S, Wang J, et al. SF3B1/Hsh155 
HEAT motif mutations affect interaction with the splice- 
osomal ATPase Prp5, resulting in altered branch site se-
lectivity in pre-mRNA splicing. Genes Dev. 2016; 30(24): 
2710–2723, doi: 10.1101/gad.291872.116, indexed in Pubmed: 
28087715.
62. Malcovati L, Papaemmanuil E, Bowen DT, et al. Clinical sig-
nificance of SF3B1 mutations in myelodysplastic syndromes 
105Novel prognostic molecular factors: a quantum leap in chronic lymphocytic leukemia
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2017
10.5603/FHC.a2017.0019
www.fhc.viamedica.pl
and myelodysplastic/myeloproliferative neoplasms. Blood. 
2011; 118(24): 6239–6246, doi: 10.1182/blood-2011-09-377275.
63. Foà R, Del Giudice I, Guarini A, et al. Clinical implications 
of the molecular genetics of chronic lymphocytic leukemia. 
Haematologica. 2013; 98(5): 675–685, doi: 10.3324/haema-
tol.2012.069369, indexed in Pubmed: 23633543.
64. Tripathi R, Lee-Verges E, Higashi M, et al. New drug discov-
ery approaches targeting recurrent mutations in chronic lym-
phocytic leukemia. Expert Opin Drug Discov. 2017; 12(10): 
1041–1052, doi: 10.1080/17460441.2017.1362387, indexed in 
Pubmed: 28776453.
65. Mitsui T, Koiso H, Nakahashi H, et al. SF3B1 and IGHV 
gene mutation status predict poor prognosis in Japanese CLL 
patients. Int J Hematol. 2016; 103(2): 219–226, doi: 10.1007/ 
s12185-015-1912-z, indexed in Pubmed: 26588928.
66. Te Raa GD, Derks IAM, Navrkalova V, et al. The impact 
of SF3B1 mutations in CLL on the DNA-damage response. 
Leukemia. 2015; 29(5): 1133–1142, doi: 10.1038/leu.2014.318, 
indexed in Pubmed: 25371178.
67. Wang L, Brooks AN, Fan J, et al. Transcriptomic charac-
terization of SF3B1 mutation reveals its pleiotropic effects 
in chronic lymphocytic leukemia. Cancer Cell. 2016; 30(5): 
750–763, doi: 10.1016/j.ccell.2016.10.005, indexed in Pubmed: 
27818134.
68. Wan Y, Wu CJ. SF3B1 mutations in chronic lymphocytic 
leukemia. Blood. 2013; 121(23): 4627–4634, doi: 10.1182/ 
blood-2013-02-427641, indexed in Pubmed: 23568491.
69. Landau DA, Carter SL, Stojanov P, et al. Evolution and im-
pact of subclonal mutations in chronic lymphocytic leukemia. 
Cell. 2013; 152(4): 714–726, doi: 10.1016/j.cell.2013.01.019, 
indexed in Pubmed: 23415222.
70. Baliakas P, Hadzidimitriou A, Sutton LA, et al. European 
Research Initiative on CLL (ERIC). Recurrent mutations 
refine prognosis in chronic lymphocytic leukemia. Leukemia. 
2015; 29(2): 329–336, doi: 10.1038/leu.2014.196, indexed in 
Pubmed: 24943832.
71. Rossi D, Bruscaggin A, Spina V, et al. Mutations of the SF3B1 
splicing factor in chronic lymphocytic leukemia: association 
with progression and fludarabine-refractoriness. Blood. 2011; 
118(26): 6904–6908, doi: 10.1182/blood-2011-08-373159, in-
dexed in Pubmed: 22039264.
72. Rasi S, Khiabanian H, Ciardullo C, et al. Clinical impact 
of small subclones harboring NOTCH1 , SF3B1 or BIRC3 
mutations in chronic lymphocytic leukemia. Haematologica. 
2016; 101(4): e135–e138, doi: 10.3324/haematol.2015.136051.
73. Campregher PV, Hamerschlak N. Novel prognostic gene mu-
tations identified in chronic lymphocytic leukemia and their 
impact on clinical practice. Clin Lymphoma Myeloma Leuk. 
2014; 14(4): 271–276, doi: 10.1016/j.clml.2013.12.016, indexed 
in Pubmed: 24548608.
74. Dreger P, Schnaiter A, Zenz T, et al. TP53, SF3B1, and 
NOTCH1 mutations and outcome of allotransplantation 
for chronic lymphocytic leukemia: six-year follow-up of the 
GCLLSG CLL3X trial. Blood. 2013; 121(16): 3284–3288, doi: 
10.1182/blood-2012-11-469627, indexed in Pubmed: 23435461.
75. National Center for Biotechnology Information resour ces. 
BIRC3 baculoviral IAP repeat containing 3 [(human)]. https://
www.ncbi.nlm.nih.gov/gene/330 (September 27, 2017).
76. Silke J, Vaux DL. Two kinds of BIR-containing protein in-
hibitors of apoptosis, or required for mitosis. J Cell Sci. 2001; 
114(Pt 10): 1821–1827, indexed in Pubmed: 11329368.
77. Bertrand MJM, Lippens S, Staes An, et al. cIAP1/2 are direct 
E3 ligases conjugating diverse types of ubiquitin chains to 
receptor interacting proteins kinases 1 to 4 (RIP1-4). PLoS 
One. 2011; 6(9): e22356, doi: 10.1371/journal.pone.0022356, 
indexed in Pubmed: 21931591.
78. Balakrishnan K, Fu M, Onida F, et al. Reactivation of 
Smac-mediated apoptosis in chronic lymphocytic leukemia 
cells: mechanistic studies of Smac mimetic. Oncotarget. 2016; 
7(26): 39458–39472, doi: 10.18632/oncotarget.8462, indexed 
in Pubmed: 27223062.
79. Huang Hk, Joazeiro CA, Bonfoco E, et al. The inhibitor of 
apoptosis, cIAP2, functions as a ubiquitin-protein ligase and 
promotes in vitro monoubiquitination of caspases 3 and 7. 
J Biol Chem. 2000; 275(35): 26661–26664, doi: 10.1074/jbc.
C000199200, indexed in Pubmed: 10862606.
80. Vallabhapurapu S, Matsuzawa A, Zhang W, et al. Nonredun-
dant and complementary functions of TRAF2 and TRAF3 in 
a ubiquitination cascade that activates NIK-dependent alter-
native NF-kappaB signaling. Nat Immunol. 2008; 9(12): 1364–
–1370, doi: 10.1038/ni.1678, indexed in Pubmed: 18997792.
81. Choudhary S, Kalita M, Fang L, et al. Inducible tumor ne-
crosis factor (TNF) receptor-associated factor-1 expression 
couples the canonical to the non-canonical NF-kB pathway in 
TNF stimulation. J Biol Chem. 2013; 288(20): 14612–14623, 
doi: 10.1074/jbc.M113.464081, indexed in Pubmed: 23543740.
82. Yamato A, Soda M, Ueno T, et al. Oncogenic activity of 
BIRC2 and BIRC3 mutants independent of nuclear fac-
tor-kB-activating potential. Cancer Sci. 2015; 106(9): 1137–
–1142, doi: 10.1111/cas.12726, indexed in Pubmed: 26094954.
83. Rose-Zerilli MJJ, Forster J, Parker H, et al. ATM mutation 
rather than BIRC3 deletion and/or mutation predicts reduced 
survival in 11q-deleted chronic lymphocytic leukemia: data 
from the UK LRF CLL4 trial. Haematologica. 2014; 99(4): 
736–742, doi: 10.3324/haematol.2013.098574, indexed in Pub-
med: 24584352.
84. Nabhan C, Raca G, Wang YL. Predicting prognosis in chronic 
lymphocytic leukemia in the contemporary era. JAMA On-
col. 2015; 1(7): 965–974, doi: 10.1001/jamaoncol.2015.0779, 
indexed in Pubmed: 26181643.
85. Del Po, Ragusa D, Buccisano F, et al. Genomic aberrations 
dramatically improve the strong prognostic impact of IGHV 
mutational status in chronic lymphocytic leukemia (CLL). 
Blood. 2013; 122: 1370.
86. Landau DA, Wu CJ. Chronic lymphocytic leukemia: molec-
ular heterogeneity revealed by high-throughput genomics. 
Genome Med. 2013; 5(5): 47, doi: 10.1186/gm451, indexed 
in Pubmed: 23731665.
87. Chiaretti S, Marinelli M, Del Giudice I, et al. NOTCH1, 
SF3B1, BIRC3 and TP53 mutations in patients with chron-
ic lymphocytic leukemia undergoing first-line treatment: 
correlation with biological parameters and response to 
treatment. Leuk Lymphoma. 2014; 55(12): 2785–2792, 
doi: 10.3109/10428194.2014.898760, indexed in Pubmed: 
24597984.
88. Xia Yi, Fan L, Wang Li, et al. Frequencies of SF3B1, 
NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 
disruptions in Chinese with chronic lymphocytic leukemia: dis-
parities with Europeans. Oncotarget. 2015; 6(7): 5426–5434, 
doi: 10.18632/oncotarget.3101, indexed in Pubmed: 25605254.
89. Amaya-Chanaga CI, Rassenti LZ. Biomarkers in chronic lym-
phocytic leukemia: Clinical applications and prognostic mark-
ers. Best Pract Res Clin Haematol. 2016; 29(1): 79–89, doi: 
10.1016/j.beha.2016.08.005, indexed in Pubmed: 27742074.
90. Iwasaki A, Medzhitov R, Iwasaki A, et al. Regulation of adap-
tive immunity by the innate immune system. Science. 2010; 
327(5963): 291–295, doi: 10.1126/science.1183021, indexed 
in Pubmed: 20075244.
106 Ewelina Zakrzewska et al.
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2017
10.5603/FHC.a2017.0019
www.fhc.viamedica.pl
91. Vandenbon A, Teraguchi S, Akira S, et al. Systems biology ap-
proaches to toll-like receptor signaling. Wiley Interdiscip Rev 
Syst Biol Med. 2012; 4(5): 497–507, doi: 10.1002/wsbm.1178, 
indexed in Pubmed: 22714995.
92. Ngo VuN, Young RM, Schmitz R, et al. Oncogenically active 
MYD88 mutations in human lymphoma. Nature. 2011; 470(7332): 
115–119, doi: 10.1038/nature09671, indexed in Pubmed: 21179087.
93. Treon S, Xu L, Yang G, et al. MYD88 L265P somatic mu-
tation in Waldenström’s macroglobulinemia. N Engl J Med. 
2012; 367(9): 826–833, doi: 10.1056/nejmoa1200710.
94. Wang JQ, Jeelall YS, Ferguson LL, et al. Toll-like receptors 
and cancer: MYD88 mutation and inflammation. Front Im-
munol. 2014; 5: 367, doi: 10.3389/fimmu.2014.00367, indexed 
in Pubmed: 25132836.
95. Jeromin S, Weissmann S, Haferlach C, et al. SF3B1 muta-
tions correlated to cytogenetics and mutations in NOTCH1, 
FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL 
patients. Leukemia. 2014; 28(1): 108–117, doi: 10.1038/ 
leu.2013.263, indexed in Pubmed: 24113472.
96. Putowski M, Podgórniak M, Piróg M, et al. Prognostic im-
pact of NOTCH1, MYD88, and SF3B1 mutations in Polish 
patients with chronic lymphocytic leukemia. Pol Arch Intern 
Med. 2017; 127(4): 238–244, doi: 10.20452/pamw.3998, in-
dexed in Pubmed: 28424451.
97. Pospisilova S, Gonzalez D, Malcikova J, et al. European Re-
search Initiative on CLL (ERIC). ERIC recommendations 
on TP53 mutation analysis in chronic lymphocytic leukemia. 
Leukemia. 2012; 26(7): 1458–1461, doi: 10.1038/leu.2012.25, 
indexed in Pubmed: 22297721.
98. Krzywinski M, Schein J, Birol I, et al. Circos: an information 
aesthetic for comparative genomics. Genome Res. 2009; 
19(9): 1639–1645, doi: 10.1101/gr.092759.109, indexed in 
Pubmed: 19541911.
99. Rosenquist R, Cortese D, Bhoi S, et al. Prognostic markers 
and their clinical applicability in chronic lymphocytic leu-
kemia: where do we stand? Leuk Lymphoma. 2013; 54(11): 
2351–2364, doi: 10.3109/10428194.2013.783913, indexed in 
Pubmed: 23480493.
Submitted: 25 July, 2017 
Accepted after reviews: 4 October, 2017 
Available as AoP: 9 October, 2017
